Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial

M. Rienstra, AC. Woite-Silva, A. Kuijper, S. Eijsbouts, K. Kraaier, T. Janota, C. Van Ofwegen, Y. Tuininga, E. Badings, JL. Merino, JN. Ruskin, AJ. Camm, PR. Kowey, C. Dufton, J. Maupas, D. Parsell, L. Belardinelli

. 2025 ; 27 (4) : . [pub] 20250328

Language English

Document type Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III

Persistent link   https://www.medvik.cz/link/bmc25016335

Grant support
InCarda Therapeutics Inc

AIMS: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. New treatments are needed to cardiovert recent-onset paroxysmal AF quickly and safely. RESTORE-1 was a multicentre, randomized, double-blind, placebo-controlled trial of a 120 mg orally inhaled solution of flecainide acetate (FlecIH-103) for cardioversion of symptomatic, recent-onset (≤48 h) paroxysmal AF. The study aim was to evaluate the efficacy and safety of FlecIH-103 administered via oral inhalation. METHODS AND RESULTS: Patients experiencing a recent-onset paroxysmal AF episode were randomized to receive a single dose of FlecIH-103 or placebo delivered over two 3.5 min inhalation periods, while patients were monitored using 12-lead electrocardiograms and Holter. The trial was stopped prematurely after treating 55 patients, due to lower-than-expected conversion rates and plasma levels. Mean age was 59.6 years, 31.5% of patients were female, and 59.2% were having their first AF episode. Conversion rate was 30.8% (95% confidence interval: 14.7-43.8) for the active group (n = 39) and 0.0% for the placebo group (n = 12) (P = 0.04). Median time to conversion was 12.8 min (IQR: 17.2). In the active group, the mean flecainide plasma level was 198 ng/mL (SD: 156), which is ∼50% lower than in the previous studies. The most common adverse events (AEs) were dysgeusia, dyspnoea, and cough. All AEs were short-lasting and of mild or moderate intensity. CONCLUSION: Despite early termination of the trial, FlecIH-103 was significantly more effective than placebo in cardioverting AF. Safety data did not show any serious AEs. Further studies of FlecIH-103 are needed to optimize the combination of drug formulation and inhalation delivery platform. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov, unique identifier: NCT05039359.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016335
003      
CZ-PrNML
005      
20250731092836.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euaf064 $2 doi
035    __
$a (PubMed)40132102
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a x
100    1_
$a Rienstra, Michiel $u Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands $1 https://orcid.org/000000022581070X
245    10
$a Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial / $c M. Rienstra, AC. Woite-Silva, A. Kuijper, S. Eijsbouts, K. Kraaier, T. Janota, C. Van Ofwegen, Y. Tuininga, E. Badings, JL. Merino, JN. Ruskin, AJ. Camm, PR. Kowey, C. Dufton, J. Maupas, D. Parsell, L. Belardinelli
520    9_
$a AIMS: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. New treatments are needed to cardiovert recent-onset paroxysmal AF quickly and safely. RESTORE-1 was a multicentre, randomized, double-blind, placebo-controlled trial of a 120 mg orally inhaled solution of flecainide acetate (FlecIH-103) for cardioversion of symptomatic, recent-onset (≤48 h) paroxysmal AF. The study aim was to evaluate the efficacy and safety of FlecIH-103 administered via oral inhalation. METHODS AND RESULTS: Patients experiencing a recent-onset paroxysmal AF episode were randomized to receive a single dose of FlecIH-103 or placebo delivered over two 3.5 min inhalation periods, while patients were monitored using 12-lead electrocardiograms and Holter. The trial was stopped prematurely after treating 55 patients, due to lower-than-expected conversion rates and plasma levels. Mean age was 59.6 years, 31.5% of patients were female, and 59.2% were having their first AF episode. Conversion rate was 30.8% (95% confidence interval: 14.7-43.8) for the active group (n = 39) and 0.0% for the placebo group (n = 12) (P = 0.04). Median time to conversion was 12.8 min (IQR: 17.2). In the active group, the mean flecainide plasma level was 198 ng/mL (SD: 156), which is ∼50% lower than in the previous studies. The most common adverse events (AEs) were dysgeusia, dyspnoea, and cough. All AEs were short-lasting and of mild or moderate intensity. CONCLUSION: Despite early termination of the trial, FlecIH-103 was significantly more effective than placebo in cardioverting AF. Safety data did not show any serious AEs. Further studies of FlecIH-103 are needed to optimize the combination of drug formulation and inhalation delivery platform. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov, unique identifier: NCT05039359.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x farmakoterapie $x diagnóza $x patofyziologie $7 D001281
650    _2
$a ženské pohlaví $7 D005260
650    12
$a flekainid $x aplikace a dávkování $x škodlivé účinky $7 D005424
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a aplikace inhalační $7 D000280
650    _2
$a výsledek terapie $7 D016896
650    _2
$a senioři $7 D000368
650    12
$a antiarytmika $x aplikace a dávkování $x škodlivé účinky $7 D000889
650    _2
$a časové faktory $7 D013997
650    12
$a srdeční frekvence $x účinky léků $7 D006339
650    _2
$a elektrokardiografie ambulantní $7 D015716
650    _2
$a předčasné ukončení klinických zkoušek $7 D057239
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
700    1_
$a Woite-Silva, Anderson C $u InCarda Therapeutics, Newark, CA, USA $1 https://orcid.org/0000000170574964
700    1_
$a Kuijper, Aaf $u Department of Cardiology, Spaarne Gasthuis, Haarlem, The Netherlands $1 https://orcid.org/0000000241548836
700    1_
$a Eijsbouts, Sabine $u Department of Cardiology, Maxima Medical Center, Veldhoven, The Netherlands $1 https://orcid.org/0000000192778255
700    1_
$a Kraaier, Karin $u Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
700    1_
$a Janota, Tomas $u Department of Cardiology, General University Hospital, Prague, Czechia
700    1_
$a Van Ofwegen, Clara $u Department of Cardiology, Diakonessenhuis, Utrecht, The Netherlands $1 https://orcid.org/0009000788445862
700    1_
$a Tuininga, Ype $u Department of Cardiology, Deventer Hospital, Deventer, The Netherlands
700    1_
$a Badings, Erik $u Department of Cardiology, Deventer Hospital, Deventer, The Netherlands $1 https://orcid.org/0000000317771779
700    1_
$a Merino, Jose Luis $u Department of Cardiology, La Paz University Hospital, IdiPaz, Universidad Autonoma, Madrid, Spain $1 https://orcid.org/0000000217371903
700    1_
$a Ruskin, Jeremy N $u Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA, USA $1 https://orcid.org/0000000170484328
700    1_
$a Camm, A John $u Cardiovascular and Genetics Research Institute, St. George's University of London, London, UK
700    1_
$a Kowey, Peter R $u Division of Cardiovascular Diseases, Lankenau Heart Institute, Wynnewood, PA, USA $1 https://orcid.org/0000000171891638
700    1_
$a Dufton, Christopher $u InCarda Therapeutics, Newark, CA, USA
700    1_
$a Maupas, Jean $u InCarda Therapeutics, Newark, CA, USA $1 https://orcid.org/0009000359237192
700    1_
$a Parsell, Dawn $u InCarda Therapeutics, Newark, CA, USA $u Parsell Consulting, Cedar Park, TX, USA
700    1_
$a Belardinelli, Luiz $u InCarda Therapeutics, Newark, CA, USA
773    0_
$w MED00149837 $t Europace $x 1532-2092 $g Roč. 27, č. 4 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40132102 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731092830 $b ABA008
999    __
$a ok $b bmc $g 2366891 $s 1253460
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 27 $c 4 $e 20250328 $i 1532-2092 $m Europace $n Europace $x MED00149837
GRA    __
$p InCarda Therapeutics Inc
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options